REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
11

Optimizing My CJC-1295 (no DAC) Protocol

Milan Fletcher·about 2 months ago
I have been fine-tuning my CJC-1295 (no DAC) protocol over the past several months and wanted to share what I have learned through trial and error. Started with the standard recommended dosing but found I respond better to a slightly modified approach. The key change was splitting my daily dose into two administrations rather than one. This gave me more even effects throughout the day without the spike-and-crash pattern I was experiencing. Reconstitution: I use bacteriostatic water exclusively. I reconstitute enough for about 2 weeks at a time and keep it refrigerated. After the first couple of batches, I got the technique dialed in pretty well. Pro tip: use insulin syringes for precision — the smaller gauge needle also makes injections nearly painless. I also want to mention that I got bloodwork done at baseline, 4 weeks, and 8 weeks. This is something I would strongly recommend for anyone running CJC-1295 (no DAC). Having objective data to compare alongside subjective improvements gives you a much clearer picture of what is happening. Currently planning to run this for a total of 12 weeks before taking a break to reassess.

Comments (4)

Bay DunneDEMO·about 2 months ago

I have been stacking CJC-1295 (no DAC) with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

2
Ember CarrollDEMO·about 2 months ago

Real talk: CJC-1295 (no DAC) worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

3
Parker HewittDEMO·about 2 months ago

Interesting data. My CJC-1295 (no DAC) experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

4
Petra CurtisDEMO·about 2 months ago

This thread has been incredibly helpful for understanding CJC-1295 (no DAC). I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

5

Sign in to comment.